ReviewPharmacogenomics and personalized medicine2016
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents.
Review in Pharmacogenomics and personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.Genome medicine · 2026Article
- Precision Medicine in Diabetes.Handbook of experimental pharmacology · 2023Article
- Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes.The review of diabetic studies : RDS · 2020Article
- Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?Clinical pharmacology and therapeutics · 2019Review
- Article
- Precision Diabetes Is Slowly Becoming a Reality.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Review
- Precision Medicine in Non Communicable Diseases.International journal of molecular and cellular medicine · 2019Review
- Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes.Diabetologia · 2017Article
- Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo population.Biomedical reports · 2017Article
- Precision diabetes: learning from monogenic diabetes.Diabetologia · 2017Review
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.Drug design, development and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes is one of the leading causes of morbidity and mortality, consuming a significant proportion of public health spending. Oral hypoglycemic agents (OHAs) are the frontline treatment approaches after lifestyle changes. However, huge interindividual variation in response to OHAs results in unnecessary treatment failure. In addition to nongenetic factors, genetic factors are thought to contribute to much of such variability, highlighting the importance of the potential of pharmacogenetics to improve therapeutic outcome. Despite the presence of conflicting results, significant progress has been made in an effort to identify the genetic markers associated with pharmacokinetics, pharmacodynamics, and ultimately therapeutic response and/or adverse outcomes to OHAs. As such, this article presents a comprehensive review of current knowledge on pharmacogenetics of OHAs and provides insights into knowledge gaps and future directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.